Micropapillary Carcinoma of the Breast

http://www.OncoPathology.info.

-Micropapillary breast carcinoma (or invasive micropapillary carcinoma IMPC) is a type of otherwise ‘typical’ invasive ductal carcinoma which exhibits a unique and characteristic growth pattern.

 -Invasive micropapillary breast carcinoma is a very aggressive form of breast cancer, with a very high rate of lymph node metastasis.(The rate of lymph node involvement is estimated at between 75% and 100%).
-Skin invovlement (skin retraction) is another occassional feature of invasive micropapillary carcinoma of the breast, and is observed in about 20-23% of all cases.
Histological aspects of invasive micropapillary carcinoma of the breast
Histologically, invasive micropapillary breast carcinoma is characterized by:
-Clusters of cohesive tumor cells within quite prominent ‘clear spaces’, which resemble dilated angiolymphatic vessels.
-The nuclei of tumor cells around the periphery can often bulge with a kind of ‘knobby’ appearance.
- It is also quite common to see lymphatic involvement with invasive micropapillary breast cancers.

The aggressiveness of invasive micropapillary carcinoma may be related to the inverse polarity of the tumor cell clusters and lymphotropism
-Invasive micropapillary breast carcinoma tumors will often show lymphocytic infiltration.
-They tend to accumlate in the breast stroma, often forming a lymphoid follicle. The presence of lymphocytes within the tumor will tend to suggest a more aggressive cancer; more likely to metastize to the lymph nodes.
-Invasive micropapillary breast cancer is also characterized histologically by an ‘inverse polarity’ of the tumor cell clusters. To clarify, within the breast the ‘functional unit’ of the breast duct wall is a ‘polar’ double-layered tube consisting of luminal epithelial cells surrounded by myoepithelial cells and a basement membrane. In other words, there is an order; an asymmetrical organization from ‘outer to inner’, and without this polarity, the breast ducts would not able to properly excrete and transport breast milk. But with micropapillary breast carcinoma (and some other breast cancers) this polarity is reversed. The clusters of malignant cells which formed have the myoepithelial cells outside of the epithelial-derived cells, with the basal layer exposed.
Hormone receptor status is high for micropapillary breast cancer, somewhat against the norm
-Breast cancers which have higher positive rates for various hormone receptors are usually considered to have a more positive outlook. For one thing, they tend to be more responsive to chemotherapy.
-With invasive micropapillary breast cancers, about 70% tend to be ER positive and around 60% are positive for progesterone receptors. HER2 overexpression may be anticipated in approximately 40% of cases.
-For most breast cancers this degree of positive hormone receptivity would be a hopeful indicator.
-In invasive micropapillary breast carcinoma,however, hormone receptor status appears to have no particular significance to the outlook.
Factors most likely to affect the prognosis of invasive micropapillary breast cancer
-The mortality rate for micropapillary breast cancer is unfortunately quite high, at over 40%.
-The average interval between full presentation of the disease and death is about 3 years. -The factors which seem most likely to affect a poor prognosis are skin involvement, and nodal status.
-However, once lymph node metastasis is confirmed, the outlook for invasive micropapillary breast cancer does not differ significantly from other breast cancers which have metastized to the lymph nodes.
-Skin invasion is a signficant predictor of a poor prognosis with invasive micropapillary breast cancer, leading to mortality in about 50% of all cases in which it occurs.
-Aspects of the tumor which are most likely to influence the risk of metastasis are the histologic grade (based on the number of atypical cells and the rate of mitosis), lymphocyte infiltration, and lymphatic vessel density.
Treatment for invasive micropapillary carcinoma of the breast
-Invasive micropapillary breast carcinoma is a highly aggressive from of breast cancer which requires the earliest possible diagnosis and aggressive intervention and management.
-The high rate of local recurrence and high probability of lymph node metastasis will usually prompt the surgeon to suggest either a modified or full radical mastectomy, though breast conserving surgery is attempted in a minority of situations.
- Axillary dissection will usually accompany a modified or radical mastectomy.
-Adjuvant treatment with chemotherapy is often utilized as well, but usually only if there is evidence of axillary node metastasis, or when there is not yet lymph node metastasis but the tumor is larger than 1 cm.
Visit http://www.OncoPathology.info for more posts.

Source:
http://feedproxy.google.com/~r/pathtalk/~3/K0pOMPZbxTw/2330

Digital Pathology Association Launches First Conference Mobile App

The Digital Pathology Association’s (DPA) annual conference Pathology Visions, being held October 28-31, 2012, is quickly approaching. To ensure that attendees stay as connected as possible with conference events the DPA has created a Pathology Visions mobile app. This will...

Source:
http://feedproxy.google.com/~r/DigitalPathologyBlog/~3/Yi8YmSl-c6c/digital-pathology-association-launches-first-conference-mobile-app.html

Advanced Options for Users of Leica Total Digital Pathology

Nussloch, Germany (October 22, 2012) Leica Biosystems, provider of world-leading Total Digital Pathology solutions, introduces two new product offerings to their portfolio. Digital Pathology use cases are multifaceted and these new solutions provide direct support for two of the fastest...

Source:
http://feedproxy.google.com/~r/DigitalPathologyBlog/~3/tTuPOuIlyeQ/advanced-options-for-users-of-leica-total-digital-pathology-.html

Olympus VS120® Virtual Slide Microscope System Now Offers Darkfield Illumination for Unstained and Fluorescent Specimens

CENTER VALLEY, Pa., October 15, 2012 – Olympus now offers researchers doing whole slide imaging the option of using darkfield illumination to image specimens on its high-performance VS120® virtual slide microscope system. The VS120, a robust whole slide imaging system...

Source:
http://feedproxy.google.com/~r/DigitalPathologyBlog/~3/3HPSnlQTDZM/olympus-vs120-virtual-slide-microscope-system-now-offers-darkfield-illumination-for-unstained-and-fl.html

Digital Pathology Debate Continues: Hope or Hype?

Courtesy of Dark Daily: During Pathology Informatics 2012, a record crowd gathered last week to explore how new technologies are reshaping both clinical laboratory informatics and anatomic pathology informatics. If there was clear consensus on any single point, it was...

Source:
http://feedproxy.google.com/~r/DigitalPathologyBlog/~3/gNQdQXh45QU/digital-pathology-debate-continues-hope-or-hype.html

Institute of Medicine Published Anticipated Study on AFIP Tissue Repository

The Institute of Medicine (IOM) has published its much anticipated study on the future use of the Department of Defense’s (DoD) biorepository (previously known as the AFIP Tissue Repository) which was created fromseveral decades of collecting tissue samples from military...

Source:
http://feedproxy.google.com/~r/DigitalPathologyBlog/~3/uB29ow_9r0w/institute-of-medicine-published-anticipated-study-on-afip-tissue-repository.html

Are you Ready for Pathology Visions 2012?

ARE YOU READY FOR PATHOLOGY VISIONS 2012? Register for Pathology Visions 2012 Pathology Visions will give you the opportunity to learn about real-world, practical applications in the ever-evolving field of digital pathology. The Digital Pathology Association’s annual meeting will give...

Source:
http://feedproxy.google.com/~r/DigitalPathologyBlog/~3/iBJSH9IXqMY/are-you-ready-for-pathology-visions-2012register-for-pathology-visions-2012pathology-visions-will-give-you-the-opp.html

Pathology Visions 2012 to Offer Regulatory Update

At the Digital Pathology Associations (DPA) upcoming annual conference Pathology Visions, being held October 28-30, 2012 in Baltimore, MD, the College of American Pathologists (CAP) Pathology and Laboratory Quality Center will be featuring a special presentation to follow up from the Regulatory Panel featured at Pathology Visions 2011.

Indianapolis, IN (PRWEB) October 18, 2012

The DPA hosted a Regulatory Panel in 2011 titled Navigating Digital Pathologys Path to Patients that gave participants a new insight into the evolving regulatory process for digital pathology products. Now at Pathology Visions 2012, the DPA is yet again highlighting the movement towards validating whole slide images.

CAP Pathology and Laboratory Quality Centers presentation for Pathology Visions 2012 titled Recommendations for Validating Whole Slide Imaging for Diagnostic Purposes in Pathology will focus on answering the question: what needs to be done to validate a whole slide digital imaging system for diagnostic purposes before it is placed in clinical service? The panel making the presentation includes Dr. Liron Pantanowitz, MD, FCAP, Chair; Anil Parwani, MD, PhD, FCAP and Andrew Evans, MD,PhD, FCAP. These panelists conducted a systematic review of international literature and addressed intended use, preparation types, case numbers, equipment, personnel, and process to reach their final recommendations included in the presentation.

In addition to the Regulatory Update, there will be over 40 presenters featured at Pathology Visions 2012. These presentations give attendees the opportunity to earn 11 continuing medical education (CME) credits throughout the conference.

Registration for Pathology Visions is still open. Please click here to register now and visit our website for more information on the Regulatory Update, CME credit and a complete list of the presenters and their topics.

About the Digital Pathology Association

The Digital Pathology Association, located in Indianapolis, IN, was founded in 2009. Its mission is to facilitate education and awareness of digital pathology applications in healthcare and life sciences. Members are encouraged to share best practices and promote the use of technology among colleagues in order to demonstrate efficiencies, awareness, and its ultimate benefits to patient care. To learn more about the DPA and Pathology Visions, please visit our website.

Michael F. Ward, CAE Digital Pathology Association (DPA) 317.816.1630 101 Email Information

View original post here:
Pathology Visions 2012 to Offer Regulatory Update

Reaccreditation site visit set for S.C. State grad program

The Speech Pathology and Audiology Program in the Department of Health Sciences at South Carolina State University is scheduled to have a reaccreditation site visit Oct. 29-30.

The Speech-Language Pathology graduate program is accredited by the Council on Academic Accreditation in Audio and Speech-Language Pathology of the American-Speech-Language-Hearing Association. CAA is a nationally recognized accrediting body which allows public input about the accreditation process and about the graduate education program.

The public meeting will be held at 5 p.m. Monday, Oct. 29, in Belcher Hall, Room 237 on the S.C. State campus. Those wishing to comment should refer to a copy of the Standards for Accreditation and/or the CAAs Policy on Public Comment, which may be obtained by contacting the Accreditation Office at ASHA, 2200 Research Boulevard, Rockville, MD 20850; calling ASHAs Action Center at 1-800-498-2071; or accessing the documents on ASHAs website at http://www.asha.org/academic/accreditation/.

Visit link:
Reaccreditation site visit set for S.C. State grad program

Definiens closes funding round for digital pathology expansion

Definiens, a Munich-based developer of image analysis techniques and specialists in the growing field of digital pathology, recently closed a private funding round worth 10 million.

The funds will primarily be used for commercial expansion of its current business, as well as development and commercialization of products for use in clinical digital pathology procedures.

Gilde Healthcare Partners, a new investor, led the funding round, which also saw participation from existing investors and Definiens management.

Digital pathology involves the acquisition, management, and interpretation of pathology information generated from digitized tissue specimens and scanned microscopy images. As pathologists embrace digital workflows, digital pathology is rapidly becoming an essential technology for increasing productivity and improving treatment decisions and patient care, according to Definiens.

"Digitization of data is increasing across the whole field of medicine," noted Markus Rinecker of Definiens speaking to Optics.org. "Most pictures in radiology are digitized; MRIs and CT scans all are digital; the same is becoming true for the patient records and other kinds of visual information. Pathology has been one of the remaining 'analog islands'."

One reason for that has been the formidable demands on the hardware involved, since digitizing pathology images with a high enough resolution to allow meaningful analysis leads to very large files.

"The images can be enormous, with single files in the gigapixel or gigabyte arena," agreed Rinecker. "And you are unlikely to have one single picture per patient, so a patient's complete data set can easily total 1 terabyte of data. This is one reason why the field has taken a long time to evolve. Only in the last three years or so have digital scanners able to perform the task become available, from vendors such as Leica and Hamamatsu. Philips has introduced its own scanner, GE is likely to do the same and are investing heavily in the field, so big companies are starting to chase this market."

A developing value chain Once adequately scanned pathology images are available, whether from standard or confocal microscopy or other sources, Definiens digital pathology image analysis is designed to detect regions of interest. These can include specific morphologies, rare events, cells, and sub-cellular components.

"Our approach is completely different from our competitors," said Rinecker. "We analyze the pictures in a similar way to how a human being would look at it, examining objects in context, rather than strictly looking for pixels and patterns and matches. This makes the image analysis much more robust, and Definiens holds patents relating to this approach."

Cancer diagnosis is a particular focus, and an area singled out for mention in the announcement of the recent funding. "Digital Pathology combined with the right image analysis tools has the potential to transform cancer diagnosis," commented Janke Dittmer, partner at Gilde Healthcare Partners, at the time. Dittmer has now joined Definiens' supervisory board following the investment round.

Read this article:
Definiens closes funding round for digital pathology expansion

Smartphone stroke assessment shows promise

A smartphone application that assists vascular neurologists (VNs) with the assessment of possible stroke patients shows excellent agreement with the interpretations of other radiologists and independent, blinded adjudicators, say researchers. "Smartphone teleradiology assessments may offer a VN a single mobile...

Source:
http://feedproxy.google.com/~r/DigitalPathologyBlog/~3/fLfUW1DffcE/smartphone-stroke-assessment-shows-promise.html

2012 Northwestern Scientific Images Contest Winners

Scientific research often produces beautiful images. These pieces, judged by a panel of local artists, scientists and community leaders, are representative of real Northwestern research across a wide range of disciplines, including medicine, chemistry, engineering, nanotechnology and Earth science. Click...

Source:
http://feedproxy.google.com/~r/DigitalPathologyBlog/~3/wdDW8lnPRvg/2012-northwestern-scientific-images-contest-winners-scientific-research-often-produces-beautiful-images-the.html

Cerner Opening – Physician Executive – Laboratory Medicine

Cerner Corporation - Kansas City, Missouri Area Job Description Cerner's Laboratory Medicine suite of solutions offer comprehensive, fully integrated technology to automate the operational and managerial sides of the laboratory. Solutions automate processes and drive efficiencies within the anatomic and...

Source:
http://feedproxy.google.com/~r/DigitalPathologyBlog/~3/TcJXpL28rKE/cerner-opening-physician-executive-laboratory-medicine-.html

Sonic cleared to buy WA’s Healthscope

The competition regulator has allowed pathology and radiology provider Sonic Healthcare to buy the Healthscope pathology business in WA but won't allow Sonic to acquire Healthscope's pathology operations in Queensland.

Healthscope announced in May that it would sell its pathology businesses in Queensland, NSW, the ACT and WA to Sonic, subject to regulatory approval from the Australian Competition and Consumer Commission, for $100 million.

In August, the ACCC produced a statement of issues in relation to Sonic's proposed acquisition.

In September, Sonic backed away from acquiring the NSW/ACT business due to the time elapsed since the transaction was announced.

Sonic said today that it had received approval from the ACCC to acquire the WA business, for which Sonic will pay $18 million.

The sale is expected to be completed later in October.

But the ACCC had advised that it would not approve the acquisition by Sonic of Healthscope's Queensland pathology business.

Sonic said it and Healthscope were considering the ACCC's decision in respect of the Queensland business.

The ACCC said on Thursday that the proposed acquisition of the Queensland business was likely to have the effect of substantially lessening competition in the market for the supply of community pathology services in Queensland.

"The proposed acquisition in Queensland would result in the removal of a substantial competitive constraint on the two major pathology providers in that state," ACCC chairman Rod Sims said in a statement.

Read the rest here:
Sonic cleared to buy WA's Healthscope

Digital Pathology Market – Slide Scanners (Whole Slide Imaging), Analytics (Image Analysis Software), Delivery Modes …

NEW YORK, Oct. 11, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Digital Pathology Market Slide Scanners (Whole Slide Imaging), Analytics (Image Analysis Software), Delivery Modes (Web Based/Cloud Based) & Whole Slide Image Storage - Global Trends & Forecast Till 2017

http://www.reportlinker.com/p01009588/Digital-Pathology-Market--Slide-Scanners-Whole-Slide-Imaging-Analytics-Image-Analysis-Software-Delivery-Modes-Web-Based/Cloud-Based--Whole-Slide-Image-Storage---Global-Trends--Forecast-Till-2017.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

The life science industry is now witnessing the second decade of "Biologic Revolution". The adoption and up gradation of technology is increasing rapidly. Conventional practices are being replaced by advanced technologies. The perception of pathological laboratories needs to be improved as the consumer expectations and government regulations towards improved patient safety, accurate diagnosis, Electronic Medical Records (EMR) as well as personalized medicines are growing. Pathology plays a significant role in patient care. Digital pathology serves this purpose by providing a facility for digital transformation of pathology and laboratory medicine.

Digital pathology is currently gaining momentum as pathologists are seeking to achieve workflow efficiency and cost cutting in the pathological process. It provides ready access to premium quality slide images, enabling better and fast diagnosis, as well as preservation of these digital slides for future reference. The digital pathology market is driven by the factors such as reduction in laboratory expenses, improvement in operational efficiency, and treatment decisions and patient care. The rising prevalence of cancer, increasing trends in drug development, companion diagnostics, and ease of consultation are the major drivers that are slated to propel this market. However, a few pivotal factors restraining the growth of this market are FDA regulations in some regions, high cost of Digital Pathology Systems (DPS), technological problems, and conservative outlook of pathologists. There are a few well-established firms and several small ones operating in this industry. The major players in the market are Aperio Technologies, Inc. (U.S.), Ventana Medical Systems (U.S.), Leica Microsystems GmbH (Germany), Digipath (U.S.), and Hamamatsu Photonics (Japan).

The global digital pathology market is broadly segmented into two categories based on its products and application. The product category includes scanners, analytics (visualization software, information management systems and image analysis platforms), storage and communication (sharing services, software), while the application category comprises human pathology and animal pathology. Both these markets are dominated by North America in 2012, followed by Europe, Asia, and Rest of the World (RoW). The global digital pathology market is estimated to be $191.00 million in 2012, and is poised to grow at a CAGR of 12% to reach $336.61 million by 2017.

The global digital pathology market is dominated by the North America, followed by Europe, Asia, and Rest of the World. North America will continue to lead the digital pathology market for the next five years in spite of stringent FDA regulations and premarketing approvals. This is due to the increasing adoption of digital pathology systems by research labs, pharmaceutical and biotechnology companies, clinical research institutes, contract research organizations, etc. Moreover, the capacity to spend money is also driving the growth in this geography. However, a robust growth rate will be observed in Europe as vendors and manufacturers will be seen turning towards the region for regulatory reliefs. The Asian region's contribution to the global digital pathology market is also expected to pick up in the coming years, as the technology gets more recognition and becomes more cost effective.

Scope of the Report

This research report categorizes the global digital pathology market into different segments based on its products and application.

Global digital pathology market, by products

Original post:
Digital Pathology Market - Slide Scanners (Whole Slide Imaging), Analytics (Image Analysis Software), Delivery Modes ...